Tag : Inclisiran

Neurology

ORION-10: 58% Reduction in LDL With Inclisiran

Newsemia
A second phase 3 study has shown impressive reductions in LDL on top of statins with this novel agent given just twice a year. Medscape...
Latest News

The Medicines Company Announces that the ORION-10 Study of Inclisiran in ASCVD Patients Showed Durable and Potent Lowering of LDL-C with Twice-Yearly Dosing

Newsemia
PHILADELPHIA–(BUSINESS WIRE)—- $MDCO #ASCVD–The Medicines Company (NASDAQ: MDCO) today announced detailed results from ORION-10, the second of three pivotal 18-month low-density lipoprotein cholesterol (LDL-C) lowering...
Latest News

New Long-Term Data Show that Twice-a-Year Dosing with Inclisiran Results in Persistent Lowering of LDL Cholesterol with No Material Safety Observations Out to Three Years

Newsemia
MIAMI–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24MDCO&src=ctag" target="_blank"gt;$MDCOlt;/agt; lt;a href="https://twitter.com/hashtag/cholesterol?src=hash" target="_blank"gt;#cholesterollt;/agt;–The Medicines Company (NASDAQ: MDCO) today announced interim results from the ongoing ORION-3 open-label extension study (Group 1, n=290)...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World